Physician profile
Hasan Guven
NPI 1770575441
$86,153.40
in general payments reported to CMS, 2019-2025
31 companies · $53K in 2025
The $53K reported for 2025 was more than what 97% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $333 · 2021: $391 · 2022: $732 · 2023: $564 · 2024: $31K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $82K · Food and Beverage: $1,954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $82,187.50 |
| Food and Beverage | $1,954.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $82,574.72 | 2019-2025 | Watchman Access System, Watchman |
| Novartis Pharmaceuticals Corporation | $968.27 | 2019-2025 | |
| Pfizer INC. | $297.58 | 2021-2025 | |
| Novo Nordisk INC | $269.67 | 2022-2025 | Wegovy |
| Inari Medical, INC. | $253.03 | 2019-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $235.09 | 2019-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $186.51 | 2019-2025 | Camzyos, Eliquis |
| Ancora Heart, INC. | $180.74 | 2022 | |
| Celonova Biosciences, INC. | $141.52 | 2019 | |
| Livanova USA, INC. | $130.35 | 2023 | Tandemlife |
| Janssen Pharmaceuticals, INC | $109.88 | 2020-2022 | |
| Abbott Laboratories | $107.01 | 2020-2025 | Navitor, Jot Dx |
| Sanofi-Aventis U.S. LLC | $102.49 | 2021-2023 | |
| Abiomed | $100.44 | 2024 | Impella |
| Biosense Webster, INC. | $76.00 | 2024 | Carto 3 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $70.36 | 2019-2020 | |
| Irhythm Technologies, INC. | $70.27 | 2021-2023 | Zio Xt Patch |
| Medtronic, INC. | $39.76 | 2019-2023 | Abre |
| Csl Behring | $39.71 | 2020-2021 | |
| Esperion Therapeutics, INC. | $30.08 | 2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $18.88 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $17.12 | 2021 | |
| Impulse Dynamics (USA) INC. | $16.68 | 2022 | |
| Lantheus Medical Imaging, INC. | $16.67 | 2019 | |
| Scpharmaceuticals INC. | $16.62 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.05 | 2024 | Jardiance |
| Cardiovascular Systems INC. | $16.03 | 2019 | |
| Glaxosmithkline, LLC. | $14.91 | 2025 | Shingrix, Arexvy |
| Akcea Therapeutics, INC. | $14.27 | 2020 | |
| Amarin Pharma, INC. | $11.58 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hasan Guven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.